If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
PEGylated Mechano Growth Factor
Supply and ordering
Ask sales about PEG MGF availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
PEG-MGF is a polyethylene-glycol-conjugated form of MGF (Mechano Growth Factor, an IGF-1 splice variant) engineered to extend plasma stability beyond the very short native MGF half-life (minutes). The PEG conjugation strategy is identical in principle to the PEG-IFN, PEG-G-CSF, and other PEG-protein conjugates used clinically, covalent attachment of a PEG polymer at one or more reactive groups on the peptide increases hydrodynamic radius, reduces renal clearance, and shields the peptide from proteolytic cleavage. The PEG MW and attachment chemistry vary substantially across supplier sources, with different vendors using anywhere from 5 kDa to 40 kDa PEG polymers and either site-specific (single-residue) or random (multi-site) conjugation. PeptideXpo supplies PEG-MGF as a lyophilized conjugate at ≥99.0% HPLC purity. Because the PEG MW and attachment site determine the molecule's pharmacokinetics, the applicable batch COA can record the PEG polymer mass, the attachment chemistry (site-specific vs random), and the PEG-to-peptide ratio. Buyers comparing PEG-MGF across suppliers should always normalize against these parameters rather than comparing on peptide content alone, two materials labeled 'PEG-MGF' from different sources can differ by 5-10× in functional half-life depending on the PEG architecture.
Who buys this, and why
Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models. Ask sales for the COA matched to the offered or supplied lot. If the buyer's written qualification procedure requires tandem-MS sequence evidence, include it in the agreed scope before quotation rather than treating it as an automatic first-batch retest.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
PEG conjugate with variable architecture across suppliers. Confirm PEG molecular weight, attachment site, and PEG-to-peptide ratio per batch COA. Pharmacokinetic comparability across supplier sources cannot be assumed.
Selected literature
Frequently asked questions
The PEG component on PEG-MGF is not a passive shield, it actively determines the molecule's pharmacokinetics. PEG polymer MW affects hydrodynamic radius (which sets renal-clearance threshold) and the overall molecular weight, both of which set the in vivo half-life. PEG attachment chemistry (site-specific vs random) affects both the consistency of the product (random conjugation produces isomer mixtures) and the residual MGF biological activity (some attachment sites preserve activity better than others). Two PEG-MGF preparations from different suppliers can have the same nominal name but differ by 5-10× in functional half-life due to PEG-architecture differences, buyers must compare PEG MW, attachment site, and PEG-to-peptide ratio across suppliers, not just label.
PEG-MGF is the right choice for in vivo research workflows where the very short native MGF half-life (minutes) would require impractical dosing frequency. The PEGylation extends functional half-life by 10-100× depending on the PEG architecture, supporting once-daily or less-frequent dosing protocols. Unmodified MGF is the right choice for cell-culture and biochemical-assay work where the dose is added directly to a defined system and stability across hours rather than days is sufficient. Many published cell-culture studies use unmodified MGF; published in vivo studies are split between PEG-MGF and similar long-acting analogs.
